Company / Cash & Equivalents
Zoetis Cash & Equivalents History
FY2016-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$727.0M
FY2017
5-year range
-
FY2016-FY2017
Trend
-17.6%
vs FY2016
Sector context
#28 of 207
Health Care
What the data says
Zoetis's cash & equivalents of $727M is higher than 86% of companies in the Health Care sector (FY2017).
Based on SEC 10-K filings.
$727M in FY2017. Top quartile in the Health Care sector.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 207This company $727.0M Sector average $669.5M
▼
+8.6% above sector average
Key checks
Key Insights
- In FY2017, cash & equivalents decreased 17.6% year-over-year.
- Ranks #28 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 28.2%
- Strong return on equity: 49.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $727.0M | -17.6% |
| FY2016 | $882.0M | +44.6% |
As of FY2017 · SEC 10-K · Updated Jun 30, 2026